Konakion (Phytomenadione)

Phytomenadione supplies vitamin K1, which is required for the gamma‑carboxylation of clotting factors II, VII, IX and X. This modification enables the factors to bind calcium and participate effectively in the coagulation cascade, leading to proper blood clot formation.

The dose of Konakion is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and route of administration. Specific dosing regimens are individualized and should follow the prescriber’s instructions.

Use of Konakion during pregnancy or breastfeeding should be discussed with a qualified healthcare provider. While vitamin K is essential for fetal development and may be compatible with breastfeeding, professional guidance is recommended to assess risks and benefits.

To order Konakion, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Konakion contains phytomenadione (vitamin K1), the same active ingredient found in other vitamin K preparations. Compared with synthetic analogues, phytomenadione is the natural form used clinically for rapid correction of deficiency and anticoagulant reversal, offering a well‑established safety profile.

Konakion should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the product. Keep it in the original packaging until use to maintain stability and potency.

Konakion can be given by intramuscular, intravenous or oral routes, depending on the clinical indication and prescriber’s decision. The appropriate route, dosage form and administration technique are selected by the healthcare professional.

Serious risks include anaphylactic reactions, severe bleeding despite treatment, thrombosis or embolic events, and hemolysis. Patients should be monitored for any signs of hypersensitivity or unexpected clotting abnormalities during therapy.

Konakion should be avoided in individuals with known hypersensitivity to phytomenadione or any of its excipients. Caution is also advised for patients with severe liver disease, uncontrolled bleeding disorders, or those receiving conflicting anticoagulant therapies without proper monitoring.